Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: New drug information overload!


Senior Member

Status: Offline
Posts: 171
Date:
RE: New drug information overload!
Permalink  
 


Thanks, Malcolm. Appreciate your knowledge and response. I guess we all agree that it's great to have someone like you on this forum! I mean it! 

Will see my tx sensitivity early next week. Will have 3 weeks blood test coming Friday, incl. VL. They do VL at 3 weeks first because it takes a few days to get Incivek delivered here. So if your 4 weeks result is good (under 1000 or UND) you need to have the pills to hand. Pharmacies obviously do not have Incivek in stock (around USD 3600 for 42 pills). Cheers!   

 



__________________

58 yo male, HCV since 1981. Gen 1B (IL28B, CT). Diagnosed 1999,  VL before tx 100'000. Biopsy A2, F3 fibrosis. Naive, SOT (with Incivek) Oct 26, 2012. UND @ week 4, 12, 18, 24, UND 12 and 24 weeks post-RX



Guru

Status: Offline
Posts: 3398
Date:
Permalink  
 

Hi Bouba, alleles at IL28B may be CC, CT and TT. They were useful in predicting likely Interferon sensitivity, and therefore likelihood of response to SOC. If CC had a 60% chance, CT would have 40% chance and TT would have 30% chance ( give or take). There have been plenty of papers suggesting this ( polymorphism) is not as relevant in triple Rx. The Inter. sensitivity certainly is which is why I like the 4 week leadin before adding Vict.  I am CT as well,  but as I had a >2 log VL drop after 4 weeks, at least I know that I'm Inter. sensitive. Cheers.



__________________

Geno 1b, IL28B CT,  x3 prior relapser,  ex-cirrhotic, 75 yo, did 48 weeks with Victrelis/Peg./Riba.  VL 1.28m at start, UNDET. at 8 ,12 ,16 ,24 ,30  and 48 weeks.  EOT 15 Feb 2013 , UNDET. at EOT + 28 weeks. SVR!  Still Undet. at EOT +5 years

Malcolm



Senior Member

Status: Offline
Posts: 171
Date:
Permalink  
 

Here in Europe, hepatologists say there will be no alternative to the current triple tx (with Inc or Vic) in the market at least till 2014... And then they look at Gilead as a frontrunner. There will be more coming between now and then but GS 7977 has a fat chnace to be approved first.

Malcolm, you mentioned CC allele... is that the one that responds best? I have CT and the lab said I could show a moderate response ... Thanks and cheers!

 

 



__________________

58 yo male, HCV since 1981. Gen 1B (IL28B, CT). Diagnosed 1999,  VL before tx 100'000. Biopsy A2, F3 fibrosis. Naive, SOT (with Incivek) Oct 26, 2012. UND @ week 4, 12, 18, 24, UND 12 and 24 weeks post-RX



Guru

Status: Offline
Posts: 3398
Date:
Permalink  
 

Great result, Joe!

Jim, Gilead have to recoup some of the $11 billion they spent acquiring control of GS7977. It wouldn't surprise me if they just got approval for GS7977 + Peg + Riba just to sell some of the stuff! Joe's trial sounds good, but we are stuck with Peg and Riba. BTW-fish is a golden trevally from the Great Barrier Reef.



__________________

Geno 1b, IL28B CT,  x3 prior relapser,  ex-cirrhotic, 75 yo, did 48 weeks with Victrelis/Peg./Riba.  VL 1.28m at start, UNDET. at 8 ,12 ,16 ,24 ,30  and 48 weeks.  EOT 15 Feb 2013 , UNDET. at EOT + 28 weeks. SVR!  Still Undet. at EOT +5 years

Malcolm



Member

Status: Offline
Posts: 43
Date:
Permalink  
 

I'm participating in a phase 3 QUAD Rx clinical tria right nowl, which includes an NS5A replication inhibitor, protease inhibitor, Ribavirin and PegInterferon. Today I received end of week 1 results and my viral load went from 1.4 million to 53 !!!!!

__________________


Senior Member

Status: Offline
Posts: 168
Date:
Permalink  
 

It is comming up on the end of the year, no better way to take care of the stockholders then to release some early phase preliminary results to boost profits. Most of current early phase tests have a very narrow field of candadites that are eligable. We really need more development on drugs usefull to broader range of persons. I understand that you can't hit a "home run" everytime, but a lot of these early test releases are purely profit motivated.



__________________

KCCO

 

 



Guru

Status: Offline
Posts: 733
Date:
Permalink  
 

It's all about the $. Nice fish btw.

__________________

jim

GT1a, St2 Lv2 last biopsy 2002, VL  11.4m,  start triple tx 9/30/11

VL 470 @4wks.....VL 22,000 @8wks  stopped tx

Round 2-  Started 3/16/12   PSI-7977, BMS-790052, Riba Undetectable day 14

Did 24 weeks Still UND 12 weeks post tx, SVR24!!!!!!! 2/14/13

 

 

 

 

 



Guru

Status: Offline
Posts: 3398
Date:
Permalink  
 

I think there is too much early reporting in the media, of each stage of the multiple trials of the multiple new drugs. I can understand the DrugCo's want to keep Hepatologists informed of progress.  Really, do we care about a Phase 2 trial reporting 100%  SVR 4? (Gilead). It might be good for the share price, but we want SVR12 or SVR24 results from Phase 3 trials. When you study results, look at exclusions to the trials. One trial would only take patients with the IL28B CC allele! Phase 2 trials may only have ~200 participants, wheras Phase 3 trials often have 3000. In the search for Interferon-free regimes, have a good look at some of these drugs. If used without Inter. the results are pretty poor! To combat the loss of Inter., the ideal Rx regime will probably be a Quad Rx., blocking NS3, NS5, a polymerase and Riba.

So GS-7977 is now Sofosbuvir- what a mouthful, but get used to it. It appears to be the frontrunner.



-- Edited by mallani on Tuesday 13th of November 2012 02:21:59 AM

__________________

Geno 1b, IL28B CT,  x3 prior relapser,  ex-cirrhotic, 75 yo, did 48 weeks with Victrelis/Peg./Riba.  VL 1.28m at start, UNDET. at 8 ,12 ,16 ,24 ,30  and 48 weeks.  EOT 15 Feb 2013 , UNDET. at EOT + 28 weeks. SVR!  Still Undet. at EOT +5 years

Malcolm

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.